Handelsinvest Investeringsforvaltning Has $337,000 Stake in Qiagen (NYSE:QGEN)

Handelsinvest Investeringsforvaltning decreased its position in shares of Qiagen (NYSE:QGEN) by 36.1% during the 1st quarter, HoldingsChannel reports. The fund owned 7,829 shares of the company’s stock after selling 4,432 shares during the period. Handelsinvest Investeringsforvaltning’s holdings in Qiagen were worth $337,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Trexquant Investment LP acquired a new position in Qiagen during the 3rd quarter worth about $1,069,000. Treasurer of the State of North Carolina lifted its holdings in Qiagen by 0.5% during the 3rd quarter. Treasurer of the State of North Carolina now owns 103,065 shares of the company’s stock worth $4,174,000 after buying an additional 523 shares during the period. Toronto Dominion Bank acquired a new position in Qiagen during the 3rd quarter worth about $41,000. Gotham Asset Management LLC lifted its holdings in Qiagen by 194.3% during the 3rd quarter. Gotham Asset Management LLC now owns 14,521 shares of the company’s stock worth $588,000 after buying an additional 9,587 shares during the period. Finally, AQR Capital Management LLC lifted its holdings in Qiagen by 11.4% during the 3rd quarter. AQR Capital Management LLC now owns 203,104 shares of the company’s stock worth $8,226,000 after buying an additional 20,714 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Wolfe Research raised Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price objective for the company in a research report on Thursday, June 27th. Stifel Nicolaus lowered their price objective on Qiagen from $55.00 to $45.00 and set a “hold” rating for the company in a research report on Wednesday, May 1st. Finally, JPMorgan Chase & Co. lifted their price objective on Qiagen from $52.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 18th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $51.05.

Qiagen Stock Down 0.3 %

QGEN stock opened at $40.58 on Thursday. The stock’s 50 day simple moving average is $43.16 and its 200 day simple moving average is $43.49. Qiagen has a fifty-two week low of $34.74 and a fifty-two week high of $47.70. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.45 and a current ratio of 1.84. The company has a market cap of $9.26 billion, a P/E ratio of 27.21, a price-to-earnings-growth ratio of 3.15 and a beta of 0.40.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Monday, April 29th. The company reported $0.46 EPS for the quarter, topping the consensus estimate of $0.44 by $0.02. The firm had revenue of $459.00 million during the quarter, compared to the consensus estimate of $453.91 million. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. The company’s quarterly revenue was down 5.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.53 earnings per share. On average, research analysts expect that Qiagen will post 2.13 earnings per share for the current fiscal year.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.